Of note, according to a recent case report, a novel ROS1-FBXL17 (F-box and leucine-rich repeat protein 17) fusion, co-existing with CD74-ROS1 fusion was detected in a patient with lung adenocarcinoma, possibly improving sensitivity to crizotinib [41]. Here, ROS1 is linked to lung adenocarcinoma.